Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Feb 10;105(6):1462–1470. doi: 10.1002/cpt.1332

Table 2.

Distribution of newborns and infants in age categories

Drugs (n) ≥ 42 weeks PMA (n) 37 to < 42 weeks PMA (n) < 37 weeks PMA (n) PNA (days) GA (weeks) PMA (weeks) Body weight (kg) SCR (mg/dL)
Amikacin (108) 22 11 75 10 (3–625) 29 (23–41) 31 (25–127) 1.29 (0.45–11.28) 0.38 (0.2–0.96)
Gadobutrol (43) 39 4 0 212 (6–696) 40 (40–40) 70 (41–139) 7.2 (2.80–14.20) 0.27 (0.1–0.66)
Gadoterate (45) 41 4 0 266 (4–721) 40 78 (39–143) 8.00 (3.00–15.00) 0.24 (0.14–0.42)
Vancomycin (92) 22 31 39 13 (2–367) 36 (24–41) 39 (25–89) 2.61 (0.53–8.26) 0.5 (0.18–1.67)
Ampicillin (73) 5 31 37 2 (0–24) 36 (24–41) 37 (25–43) 2.47 (0.50–4.19) 0.6 (0.2–2.5)
Gentamicin (143) 46 48 49 1 (0–711) 37 (23–43) 38 (23–135) 3.12 (0.40–12.00) 0.6 (0.18–5.5)
Meropenem (200) 13 31 156 21 (1–92) 28 (23–40) 32 (24–51) 1.54 (0.39–6.50) 0.5 (0.1–1.9)
Netilmicin (83) 1 3 79 10 (2–121) 27 (23–41) 29 (24–43) 1.00 (0.47–3.00) 0.77 (0.27–1.67)
All drugs (787) 189 163 435 13 (0–721) 33 (23–43) 35 (23–143) 2.16 (0.39–15.00) 0.5 (0.1–5.5)

GA, gestational age; PMA, postmenstrual age; PNA, postnatal age; SCR, serum creatinine.